Andere talen Lisata Therapeutics, Inc.

Aandelen

LSTA

US1280583022

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,73 ^USD	-0,73%		+3,02%	-.--%

23/04	Lisata Therapeutics, Inc. en Qilu Pharmaceutical Co., Ltd kondigen de behandeling aan van de eerste patiënt in Qilu's fase 2-onderzoek in China naar LSTA1 bij patiënten met uitgezaaid pancreasductaal adenocarcinoom	CI
17/04	Lisata Therapeutics, Inc. Stelt James Nisco aan als Senior Vice President Finance and Treasury en Chief Accounting Officer	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	24/04
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	23/04
Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	23/04
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	17/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	03/04
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	21/03
Sector Update: Health Care Stocks Higher in Afternoon Trading	21/03
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	21/03
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	21/03
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	04/03
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	29/02
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	22/02
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	22/02
Lisata Therapeutics to Present at BIO CEO & Investor Conference	20/02
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico	18/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lisata Therapeutics, Inc.

Aandelen

LSTA

US1280583022

Andere talen

Filters